Business

According to a report in the Wall Street Journal, a court in Cologne, Germany has issued a preliminary injunction preventing Sandoz from marketing its AirFluSal Forspiro in Germany. GlaxoSmithKline had argued that Sandoz's salmeterol/fluticasone DPI presented unfair competition to GSK's Advair because the purple color of the Forspiro inhaler would lead consumers to … [Read more...] about GSK gets preliminary injunction preventing sales of AirFluSal Forspiro in Germany

According to Mylan, the United States District Court for the Northern District of West Virginia has upheld the validity of all of its patents related to Perforomist formoterol fumarate inhalation solution. The company says that the ruling will prevent the FDA from approving Teva's ANDA for its formoterol fumarate inhalation solution before expiration of patents … [Read more...] about US district court upholds validity of Mylan Perforomist patents

According to St. Renatus, Blue Ocean Holdings is investing an additional $5 million in the company. The funds will go toward completion of St. Renatus's New Drug Application (NDA) for its nasal mist dental anesthesia and for commercialization. St. Renatus says that it plans to submit the NDA in 2014. In February 2014, St. Renatus announced that it had completed … [Read more...] about St. Renatus gets $5 million additional funding for nasal dental anesthetic

Alexza Pharmaceuticals has announced that its European partner Ferrer has launched Adasuve loxapine inhalation powder for the treatment of agitation in schizophrenic or bipolar patients in Romania. Ferrer has a distribution agreement with Galenica for distribution in that country. In the US, Teva launched the product earlier this month. Alexza President and CEO … [Read more...] about Adasuve launched in Romania

Vectura has announced that it will acquire Activaero for a total of €130 million ($181 million). The company cited both Activaero's nebulizer technology and its pipeline of respiratory drugs as part of the rationale for the acquisition, saying that the deal "extends Vectura's technology platform into smart nebulizer-based technology, broadening Vectura's therapeutic … [Read more...] about Vectura acquires Activaero for €130 million

According to Hi-Tech Pharmacal, sales of its fluticasone propionate nasal spray dropped from $23 million in the 3rd quarter of the 2013 fiscal year to only $10.9 million for the same period in 2014. The decrease was a combination of lower unit sales and a lower average price, the company said. Sales of a homeopathic OTC nasal spray called Sinus Buster marketed by … [Read more...] about Hi-Tech Pharmacal reports large drop in nasal spray sales

Verona Pharma has announced that it is looking to raise up to £14 million through a placing, subscription, and open offer of more than 630 million new ordinary shares, conditioned on approval of shareholders. A general meeting will be held on March 24 2014. According to the company, the proceeds would be used for development of its inhaled dual phosphodiesterase (PDE) … [Read more...] about Verona looking to raise up to £14 million for development of inhaled drugs

Teva has announced the US launch of Adasuve loxapine inhalation powder for the treatment of agitation in schizophrenic or bipolar patients. The company licensed Adasuve from its developer, Alexza Pharmaceuticals in May 2013. Alexza's Staccato thermal aerosol inhaler is the delivery device. Teva Select Brands and Teva Women’s Health VP and General Manager Michael … [Read more...] about Teva launches Adasuve in US